<DOC>
	<DOCNO>NCT00502138</DOCNO>
	<brief_summary>This research project investigate effect pramlintide ( Symlin ) give continuous subcutaneous ( skin ) infusion throughout day night , along meal dos similar inject conventional pramlintide ( Symlin ) treatment , deliver use second insulin pump , subject inadequately control type I diabetes mellitus already use insulin pump therapy . Study participant wear two pump four month period , take insulin usual manner pramlintide ( Symlin ) similar basal/bolus fashion . Continuous glucose monitor wear three occasion study assess blood glucose response continuous pramlintide ( Symlin ) treatment .</brief_summary>
	<brief_title>A Pilot Study Continuous Subcutaneous Pramlintide Infusion Therapy Patients With Type 1 Diabetes</brief_title>
	<detailed_description>DESCRIPTION OF STUDY : To participate study , must Type I diabetes mellitus take insulin use insulin pump , hemoglobin A1c level 7.0 % 10.0 % . You permit participate study take pramlintide ( Symlin ) previous three month . The study consist seven visit Study Center four-month period . Subjects undergo meal tolerance test begin end study period . Continuous blood glucose monitoring perform three occasion study . Pramlintide begin single basal rate 1.5 units/hr . Bolus therapy begin thereafter per standard manufacturer protocol . Subjects monitor three month basal-bolus pramlintide therapy .</detailed_description>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>1 . Type 1 diabetes least one year duration ; 2 . Treated CSII therapy least 6 month ; 3 . Age 18 70 year , inclusive ; 4 . A1C &gt; 7.0 ≤10 % screening ; 5 . BMI ≤35 kg/m2 ; 6 . Stable insulin dose ( ±10 % ) least 3 month prior screen ; 7 . If female , negative urine pregnancy test screening ; 8 . If female childbearing potential , practice willing continue use appropriate contraception ensure pregnancy occur study ; 9 . Able understand sign require study document comply protocol requirement 1 . Is poorly compliant currently prescribe insulin regimen , determine investigator ; 2 . Has significant medical condition , laboratory finding , medical history may affect successful completion study and/or personal wellbeing ; 3 . If female childbearing potential , pregnant , lactating , plan become pregnant ; 4 . Has experience recurrent severe hypoglycemia require assistance past 6 month ; 5 . Has history hypoglycemia unawareness ; 6 . Has confirm diagnosis gastroparesis ; 7 . Requires use drug stimulate gastrointestinal motility ; 8 . Is receive medication know interfere glycemic control ( i.e . glucocorticoid ) ; 9 . Has treat oral antidiabetic agent exenatide within 3 month screen visit ; 10 . Has treat pramlintide within 3 month screen visit ; 11 . Has receive investigational drug within 3 month screen visit ; 12 . Is currently participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>diabetes</keyword>
	<keyword>insulin</keyword>
	<keyword>pramlintide</keyword>
	<keyword>IDDM</keyword>
</DOC>